ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last761 to 780 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Bleeding Complication869 of 6,110

834 of 6,101

0.6 points

-0.7 to 1.8

12,211NCT02984384

PREVENTion of Clot in Orthopaedic Trauma

Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Wound Complication14 of 6,110

8 of 6,101

0.1 points

-0.1 to 0.3

12,211NCT02984384

PREVENTion of Clot in Orthopaedic Trauma

Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: deaths from any cause45 of 6,110

47 of 6,101

-0.0 points

-0.3 to 0.3

12,211NCT02984384

PREVENTion of Clot in Orthopaedic Trauma

Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Deep Vein Thrombosis103 of 6,110

151 of 6,101

-0.8 points

-1.3 to -0.3

12,211NCT02984384

PREVENTion of Clot in Orthopaedic Trauma

Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: serious adverse events260 of 6,110

324 of 6,101

-1.1 points

-1.8 to -0.3

12,211NCT02984384

PREVENTion of Clot in Orthopaedic Trauma

Evacetrapib vs Placebo: Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke437 of 6,038

453 of 6,054

-0.2 points

-1.2 to 0.7

12,092NCT01687998

A Study of Evacetrapib in High-Risk Vascular Disease

Evacetrapib vs Placebo: Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA857 of 6,038

867 of 6,054

-0.1 points

-1.4 to 1.1

12,092NCT01687998

A Study of Evacetrapib in High-Risk Vascular Disease

Evacetrapib vs Placebo: Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)779 of 6,038

776 of 6,054

0.1 points

-1.1 to 1.3

12,092NCT01687998

A Study of Evacetrapib in High-Risk Vascular Disease

Evacetrapib vs Placebo: Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA571 of 6,038

570 of 6,054

0.0 points

-1.0 to 1.1

12,092NCT01687998

A Study of Evacetrapib in High-Risk Vascular Disease

Evacetrapib vs Placebo: Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization690 of 6,038

691 of 6,054

0.0 points

-1.1 to 1.1

12,092NCT01687998

A Study of Evacetrapib in High-Risk Vascular Disease

Evacetrapib vs Placebo: serious adverse events2,306 of 6,036

2,341 of 6,052

-0.5 points

-2.2 to 1.3

12,088NCT01687998

A Study of Evacetrapib in High-Risk Vascular Disease

Rivaroxaban 10 mg or 7.5 mg vs Placebo: deaths from any cause115 of 6,007

126 of 6,012

-0.2 points

-0.7 to 0.3

12,019NCT02111564

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Rivaroxaban 10 mg or 7.5 mg vs Placebo: serious adverse events475 of 6,007

493 of 6,012

-0.3 points

-1.3 to 0.7

12,019NCT02111564

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

D-QIV vs Control: serious adverse events217 of 6,006

201 of 6,012

0.3 points

-0.4 to 0.9

12,018NCT01439360

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Lorcaserin 10 mg vs Placebo: deaths from any cause219 of 5,995

202 of 5,992

0.3 points

-0.4 to 0.9

11,987NCT02019264

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Lorcaserin 10 mg vs Placebo: serious adverse events1,974 of 5,995

2,021 of 5,992

-0.8 points

-2.5 to 0.9

11,987NCT02019264

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

ZOSTAVAX™ vs Placebo: serious adverse events340 of 5,979

300 of 5,990

0.7 points

-0.1 to 1.5

11,969NCT00550745

ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

Idiopathic Pulmonary Fibrosis (IPF) Cohort vs Non Idiopathic Pulmonary Fibrosis (IPF) Cohort: Sustained Oxygen Therapy Use Within the First 12 Months of Follow-up967 of 1,339

4,973 of 10,592

25.3 points

22.6 to 27.8

11,931NCT05957198

Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease

Intervention Arm vs Placebo Arm: Maternal Outcome 4 - Incidence of Maternal Mortality9 of 5,958

12 of 5,948

-0.1 points

-0.2 to 0.1

11,906NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Intervention Arm vs Placebo Arm: Fetal Outcome 5 - Incidence of Spontaneous Abortion134 of 5,956

152 of 5,946

-0.3 points

-0.9 to 0.2

11,902NCT02409680

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=39

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02984384-8c8e48ee",
        "title": "Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Bleeding Complication",
        "summary": "869 of 6110 against 834 of 6101; risk difference 0.6 points, 95% interval -0.7 to 1.8; NCT02984384, PREVENTion of Clot in Orthopaedic Trauma",
        "record": "/library/comparisons/NCT02984384-8c8e48ee",
        "nct_id": "NCT02984384",
        "kind": "outcome",
        "participants": 12211,
        "risk_difference": {
          "value": 0.005526957427761964,
          "lower": -0.0067662165883062755,
          "upper": 0.017819825217260304
        },
        "group_1": "869 of 6,110",
        "group_2": "834 of 6,101",
        "difference": "0.6 points",
        "interval": "-0.7 to 1.8",
        "trial_title": "PREVENTion of Clot in Orthopaedic Trauma"
      },
      {
        "id": "NCT02984384-d2128428",
        "title": "Low Molecular Weight Heparin (LMWH)-Enoxaparin vs Acetylsalicylic Acid (ASA)-Aspirin: Wound Complication",
        "summary": "14 of 6110 against 8 of 6101; risk difference 0.1 points, 95% interval -0.1 to 0.3; NCT02984384, PREVENTion of Clot in Orthopaedic Trauma",
        "record": "/library/comparisons/NCT02984384-d2128428",
        "nct_id": "NCT02984384",
        "kind": "outcome",
        "participants": 12211,
        "risk_difference": {
          "value": 0.0009800652464743108,
          "lower": -0.0005950680566740171,
          "upper": 0.002660792865415331
        },
        "group_1": "14 of 6,110",
        "group_2": "8 of 6,101",
        "difference": "0.1 points",
        "interval": "-0.1 to 0.3",
        "trial_title": "PREVENTion of Clot in Orthopaedic Trauma"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=40",
  "request_id": "Fkm66ugtT3285Ris"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?